Clinical Trial Search

Phase 3 N=369 A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Neoplasms, Breast

Primary: Progression Free Survival (PFS) Events in Lapatinib + Trastuzumab + Aromatase Inhibitor (AI) vs. Trastuzumab + Aromatase Inhibitor (AI) — 62; 75; 7; 3 Participants…

Novartis Pharmaceuticals Results Jul 2019 17.4% serious AE View details

Phase 3 N=1,055 Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24 — 0.113; 0.095 Liter

GlaxoSmithKline Results Jul 2019 10.9% serious AE View details

Phase 3 N=31 Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I

Acute Coronary Syndrome

Primary: Change in the Total Atheroma Volume of the Target Coronary Artery From Baseline to 12 Weeks Post-PCI as Assessed Via Intravascular Ultrasound With Virtual Histology…

VA Office of Research and Development Results Jul 2019 45.2% serious AE View details

Phase 3 N=491 BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

Primary: Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 in Participants Who Received Risankizumab…

AbbVie Results Jul 2019 3.1% serious AE View details

Phase 3 N=627 Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment

HIV Infections

Primary: Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 48 — 84; 70 Percentage of participants — p=<.001

ViiV Healthcare Results Jul 2019 8.9% serious AE View details

Phase 3 N=32 Subcutaneous Lidocaine For Cancer-Related Pain

Cancer-related Pain

Primary: Number of Participants With Reduction in Worst Pain Intensity or Reduction in 24hr Opioid Dose of at Least 30% Without Worsening of Pain Scores — 1; 2; 2; 1 Participants

British Columbia Cancer Agency Results Jul 2019 0.0% serious AE View details

Phase 3 N=1,925 FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Breast Cancer

Primary: Disease-free Survival (DFS) Event — 98; 71 Participants

Spanish Breast Cancer Research Group Results Jul 2019 6.3% serious AE View details

Phase 3 N=164 Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU

Phenylketonuria (PKU)

Primary: Change From Baseline in the Blood Plasma Phenylalanine (Phe) Concentration at Part 2 — 596.8; 563.9; 410.9; 508.2 µmol/L — p=<0.0001

BioMarin Pharmaceutical Results Jul 2019 5.7% serious AE View details

Phase 3 N=17 BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent

HIV · Salivary Gland Disease · Benign Lymphoepithelial Lesion

Primary: BK Viral Status in Saliva at Week 4 — 3; 6; 5; 1 Participants

University of North Carolina, Chapel Hill Results Jul 2019 0.0% serious AE View details

Phase 3 N=249 Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat

Pharyngitis

Primary: Sum of Pain Intensity Difference (SPIDnorm)-Time-weighted Average of the Pain Intensity Difference (PID) From Pre-dose Baseline Over the First 3 Hours After the First…

Boehringer Ingelheim Results Jul 2019 0.0% serious AE View details

Phase 3 N=159 Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

Hepatitis C

Primary: Percentage of Participants With Sustained Virologic Response (SVR) at Post-Treatment Follow-up Week 24 (SVR24) — 91.2 Percentage of participants

Bristol-Myers Squibb Results Jul 2019 3.1% serious AE View details

Phase 3 N=303 LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in HbA1c — -1.00; -0.32; -1.05; -0.35 Percentage of HbA1c — p=<.001

Novo Nordisk A/S Results Jul 2019 2.0% serious AE View details

Phase 3 N=84 A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

Hepatitis C Virus (HCV)

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post Treatment (SVR12) — 95.7; 98.4 percentage of participants

AbbVie Results Jul 2019 5.9% serious AE View details

Phase 3 N=21 Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity

Urinary Bladder, Overactive

Primary: Treatment Phase 1 (Treatment Cycle 1)- Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 6 — -0.18; -3.20 Episodes

GlaxoSmithKline Results Jul 2019 6.7% serious AE View details

Phase 3 N=380 Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

Breast Cancer

Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months

Spanish Breast Cancer Research Group Results Jul 2019 22.7% serious AE View details